Ingevity (NYSE:NGVT) Posts Quarterly Earnings Results, Beats Estimates By $0.41 EPS

Ingevity (NYSE:NGVT) announced its quarterly earnings data on Wednesday. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.41, FiscalAI reports. Ingevity had a positive return on equity of 207.82% and a negative net margin of 10.55%.The company had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity updated its FY 2026 guidance to 5.000-5.450 EPS.

Ingevity Price Performance

NYSE NGVT traded down $3.41 during trading hours on Wednesday, hitting $71.08. The company had a trading volume of 387,158 shares, compared to its average volume of 202,450. Ingevity has a 52 week low of $39.74 and a 52 week high of $79.29. The firm has a 50 day simple moving average of $71.53 and a 200 day simple moving average of $70.91. The company has a debt-to-equity ratio of 27.83, a quick ratio of 0.92 and a current ratio of 1.42. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -20.02 and a beta of 1.16.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NGVT shares. Wall Street Zen upgraded shares of Ingevity from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Ingevity in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $80.00.

Insiders Place Their Bets

In other news, SVP Terrance M. Dyer sold 496 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $68.49, for a total transaction of $33,971.04. Following the sale, the senior vice president directly owned 7,202 shares in the company, valued at $493,264.98. This represents a 6.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.88% of the stock is owned by insiders.

Hedge Funds Weigh In On Ingevity

Large investors have recently modified their holdings of the company. Global Retirement Partners LLC purchased a new position in Ingevity during the fourth quarter valued at approximately $27,000. Meeder Asset Management Inc. bought a new stake in Ingevity during the 4th quarter worth approximately $33,000. Geneos Wealth Management Inc. lifted its stake in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after purchasing an additional 387 shares in the last quarter. Headlands Technologies LLC bought a new position in Ingevity in the 2nd quarter valued at $46,000. Finally, Kestra Advisory Services LLC bought a new position in Ingevity in the 4th quarter valued at $47,000. 91.59% of the stock is currently owned by institutional investors.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.